Boston, July 25, 2022 / PRNewswire /-HotSpot Therapeutics, Inc., a biotechnology company that pioneered the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today Paul Tibodo, PhD, as Chief Executive Officer. Dr. Tibodo has nearly 20 years of business development experience in the biopharmacy industry.
“We are very pleased to welcome Paul to HotSpot as Chief Business Officer,” he said. Jonathan Montag, Co-founder and Chief Executive Officer of HotSpot Therapeutics. “Paul’s significant industry experience and solid track record in biopharmacy business development will be critical to advancing oncology and autoimmunity programs and expanding the pipeline through partnerships enabled by the Smart Allostery ™ platform.”
Dr. Tibodo participated in HotSpot from Novartis, held numerous business development positions, and most recently led M & A transactions in all Novartis therapeutic areas, sourcing, evaluating and executing acquisitions and sales. Prior to joining Novartis in 2016, he was Senior Director of Global Business Development at Teva Sepharon, leading all outlicense and discovery transactions in his specialized pipeline. Previously, he held numerous business development positions while expanding Sanofi Genzyme’s responsibilities throughout the oncology, transplantation and multiple sclerosis franchises. Dr. Tibodo was a postdoctoral fellow at the National Institutes of Health (INSERM). Paris, France.. Dr. Tibodo received his PhD.Ph.D. in Cell Biology and Radiobiology from University Sherbrooke of Quebec, CanadaHe holds a Bachelor of Science degree in Biology and Biochemistry from, and Universitéde. Moncton of New Brunswick, Canada..He also got an MBA in MIT Sloan School of Business..
“We are excited to join HotSpot’s leading and innovative team at this important time for the company,” said Dr. Thibodeau. “We look forward to working with the team as they are trying to propose new treatments for patients with critical unmet needs.”
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. targets naturally occurring pockets in specific proteins, called “natural hotspots” that are critical in controlling the function of cellular proteins. These pockets, which are rarely used in the industry, have great potential for drug discovery and offer a very powerful and selective small molecule systematic design that demonstrates new pharmacology. The company’s unique Smart Allostery ™ platform leverages a computational approach and data mining of large, highly diverse datasets driven by AI to identify natural hotspots, customized pharmacology toolkits and bespoke chemistry. We believe that we will integrate with and enable rapid delivery targeting excellent hotspots. Small molecule. HotSpot has established a pipeline of differentiated allosteric small molecules for the treatment of cancer and autoimmune diseases. For more information, please visit www.hotspotthera.com.
Source HotSpot Therapeutics
..
Commentaires
Enregistrer un commentaire